Company news

Precision BioSciences, Inc. news in 2023

Precision BioSciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

December 12, 2023

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

December 3, 2023

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

November 27, 2023

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

November 8, 2023

Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023

Precision BioSciences to Report Third Quarter Results on November 7, 2023

October 31, 2023

Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

October 25, 2023

Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

September 26, 2023

Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

September 11, 2023

Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

August 30, 2023

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

August 14, 2023

Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 3, 2023

Precision BioSciences to Report Second Quarter Results on August 4, 2023

July 31, 2023

Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day

July 26, 2023

Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023

June 21, 2023

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward

May 30, 2023

Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting

May 11, 2023

Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

May 1, 2023

Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

April 17, 2023

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

April 12, 2023

European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

March 21, 2023

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

March 8, 2023

Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes

February 23, 2023

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

January 8, 2023

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

January 5, 2023

Decks in 2023